International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis

Journal of the American Medical Association

Volumn 295, Issue 2, 2006, Pages 180-189

  Bhatt, Deepak L ^a   Gabriel Steg, P ^b   Magnus Ohman, E ^c   Hirsch, Alan T ^d   Ikeda, Yasuo ^e   Mas, Jean Louis ^f   Goto, Shinya ^g   Liau, Chiau Suong ^h   Richard, Alain J ⁱ   Röther, Joachim ^j   Wilson, Peter W F ^k  

^a LERNER RESEARCH INSTITUTE   (United States)

^b BICHAT HOSPITAL   (France)

^c DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF MINNESOTA   (United States)

^e KEIO UNIVERSITY   (Japan)

^f CENTRE HOSPITALIER SAINTE ANNE   (France)

^g TOKAI UNIVERSITY   (Japan)

^h NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

ⁱ SANOFI   (France)

^j KLINIKUM MINDEN   (Germany)

^k MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACETYLSALICYLIC ACID; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIGUANIDE DERIVATIVE; BUFLOMEDIL; CALCIUM CHANNEL BLOCKING AGENT; CILOSTAZOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; NAFTIDROFURYL; NITRATE; NONSTEROID ANTIINFLAMMATORY AGENT; PENTOXIFYLLINE; SULFONYLUREA;

ADULT; AGE DISTRIBUTION; AGED; ARTERY DISEASE; ARTERY THROMBOSIS; ARTICLE; ATHEROSCLEROSIS; BLOOD PRESSURE; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; COMPARATIVE STUDY; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; EVIDENCE BASED MEDICINE; FEMALE; GEOGRAPHY; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MORBID OBESITY; NORTH AMERICA; OBESITY; OUTPATIENT; PHYSICIAN; PREVALENCE; PRIORITY JOURNAL; REGISTER; RISK REDUCTION; TOBACCO; VASCULAR DISEASE;

AGED; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; DRUG UTILIZATION; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; OUTPATIENTS; PLATELET AGGREGATION INHIBITORS; PREVALENCE; REGISTRIES; RISK FACTORS; THROMBOSIS; WORLD HEALTH;

EID: 30444453441     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.295.2.180     Document Type: Article

References (33)

1. Bhatt DL, Roe MT, Peterson ED, et al. Utilization of early invasive management strategies for high-risk patients with non-ST-segment elevation acute coronary syndromes: results from the CRUSADE Quality Improvement Initiative. JAMA. 2004;292:2096-2104.
2. Steg PG, Goldberg RJ, Gore JM, et al. Baseline characteristics, management practices, and in-hospital outcomes of patients hospitalized with acute coronary syndromes in the Global Registry of Acute Coronary Events (GRACE). Am J Cardiol. 2002;90:358-363.
3. Fox KA, Cokkinos DV, Deckers J, Keil U, Maggioni A, Steg G. The European Network for Acute Coronary Treatment (ENACT) study: a pan-European survey of acute coronary syndromes. Eur Heart J. 2000;21:1440-1449.
4. Eagle KA, Kline-Rogers E, Goodman SG, et al. Adherence to evidence-based therapies after discharge for acute coronary syndromes: an ongoing prospective, observational study. Am J Med. 2004;117:73-81.
5. Antiplatelet Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324:71-86.
6. US Preventive Services Task Force. Aspirin for the primary prevention of cardiovascular events: recommendation and rationale. Ann Intern Med. 2002;136:157-160.
7. Heart Protection Study Investigators. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:7-22.
8. CAPRIE Steering Committee. Arandomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 1996;348:1329-1339.
9. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G; Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-convertingenzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000;342:145-153.
10. Wilson PW. Framingham and European risk algorithms: implications for African Americans. Rev Cardiovasc Med. 2004;5(suppl 3):S34-S41.
11. Liu J, Hong Y, D'Agostino RB Sr, et al. Predictive value for the Chinese population of the Framingham CHD risk assessment tool compared with the Chinese Multi-Provincial Cohort Study. JAMA. 2004;291:2591-2599.
12. Ohman EM, Bhatt DL, Wilson PWF, Röther J, Steg PG; for REACH Registry Investigators. The REACH Registry: an international, prospective, observational investigation in subjects at risk of atherothrombotic events -Study design. Am Heart J. In press.
13. Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction - summary article: a report of the American College of Cardiology/ American Heart Association task force on practice guidelines (Committee on the Management of Patients With Unstable Angina). J Am Coll Cardiol. 2002;40:1366-1374.
14. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497.
15. Lee TH, Cleeman JI, Grundy SM, et al. Clinical goals and performance measures for cholesterol management in secondary prevention of coronary heart disease. JAMA. 2000;283:94-98.
16. Nissen SE, Tuzcu EM, Schoenhagen P, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA. 2004;291:1071-1080.
17. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350:1495-1504.
18. Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364:937-952.
19. Pocock SJ, Henderson RA, Seed P, Treasure T, Hampton JR. Quality of life, employment status, and anginal symptoms after coronary angioplasty or bypass surgery: 3-year follow-up in the Randomized Intervention Treatment of Angina (RITA) Trial. Circulation. 1996;94:135-142.
20. Fonarow GC, Gawlinski A, Moughrabi S, Tillisch JH. Improved treatment of coronary heart disease by implementation of a Cardiac Hospitalization Atherosclerosis Management Program (CHAMP). Am J Cardiol. 2001;87:819-822.
21. Mehta RH, Montoye CK, Gallogly M, et al. Improving quality of care for acute myocardial infarction: the Guidelines Applied in Practice (GAP) Initiative. JAMA. 2002;287:1269-1276.
22. Yusuf S, Reddy S, Ounpuu S, Anand S. Global burden of cardiovascular diseases, part I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization. Circulation. 2001;104:2746-2753.
23. Yusuf S, Reddy S, Ounpuu S, Anand S. Global burden of cardiovascular diseases, part II: variations in cardiovascular disease by specific ethnic groups and geographic regions and prevention strategies. Circulation. 2001;104:2855-2864.
24. Ramachandran A, Snehalatha C, Vijay V. Low risk threshold for acquired diabetogenic factors in Asian Indians. Diabetes Res Clin Pract. 2004;65:189-195.
25. Zhu S, Heshka S, Wang Z, et al. Combination of BMI and waist circumference for identifying cardiovascular risk factors in whites. Obes Res. 2004;12:633-645.
26. Ho SY, Lam TH, Janus ED. Waist to stature ratio is more strongly associated with cardiovascular risk factors than other simple anthropometric indices. Ann Epidemiol. 2003;13:683-691.
27. Ardern CI, Katzmarzyk PT, Janssen I, Ross R. Discrimination of health risk by combined body mass index and waist circumference. Obes Res. 2003;11:135-142.
28. Zhu S, Wang Z, Heshka S, Heo M, Faith MS, Heymsfield SB. Waist circumference and obesityassociated risk factors among whites in the Third National Health and Nutrition Examination Survey: clinical action thresholds. Am J Clin Nutr. 2002;76:743-749.
29. Wildman RP, Gu D, Reynolds K, Duan X, He J. Appropriate body mass index and waist circumference cutoffs for categorization of overweight and central adiposity among Chinese adults. Am J Clin Nutr. 2004;80:1129-1136.
30. Anuurad E, Shiwaku K, Nogi A, et al. The new BMI criteria for Asians by the regional office for the western pacific region ofWHOare suitable for screening of overweight to prevent metabolic syndrome in elder Japanese workers. J Occup Health. 2003;45:335-343.
31. Vikram NK, Pandey RM, Misra A, Sharma R, Devi JR, Khanna N. Non-obese (body mass index 25 kg/ m2) Asian Indians with normal waist circumference have high cardiovascular risk. Nutrition. 2003;19:503-509.
32. Foucan L, Hanley J, Deloumeaux J, Suissa S. Body mass index (BMI) and waist circumference (WC) as screening tools for cardiovascular risk factors in Guadeloupean women. J Clin Epidemiol. 2002;55:990-996.
33. Bhatt DL. Diffuse coronary disease and atherothrombosis: a rationale for long-term therapy to prevent recurrent ischemic events. J Invasive Cardiol. 2003;15(suppl B):3B-10B.